- Silo Pharma, Inc. announced on **September 3, 2025**, that **IP Australia** (the Australian Patent Office) has granted patent number **2020271839** to its research and licensing partner Columbia University for an invention exclusively licensed to Silo.  **[1514183_371054198b234d34a3c650b9a3882776_0]** 
- This patent reinforces protection for Silo’s lead asset, **SPC-15**, an intranasal treatment targeting **post-traumatic stress disorder (PTSD)**.  **[1514183_371054198b234d34a3c650b9a3882776_0]** 
- According to Silo CEO Eric Weisblum, this patent strengthens the company's global intellectual property portfolio for **SPC-15** and supports plans for its clinical trial development as an innovative therapeutic for PTSD.  **[1514183_371054198b234d34a3c650b9a3882776_0]** 
- **SPC-15** is a serotonin 5-HT4 receptor agonist aimed at treating stress-induced psychiatric disorders and has potential eligibility for the FDA’s streamlined **505(b)(2)** regulatory pathway.  **[1514183_371054198b234d34a3c650b9a3882776_0]**

Silo Pharma (SILO)